In particular, we found PI3K-Akt initiators; such as the RTKs EGFR1 and VEGFA, and the integrins ITGB3 and ITGB6, to be potential drug targets in ovarian cancer patients with high CTCFL expression. This evidence concerns the gene ITGB6 and ovarian carcinoma.